|

ODM-212 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since May 2026

Pipeline

Phase 1/2: 2

Top Sponsors

  • Orion Corporation, Orion Pharma2

Indications

  • Cancer2
  • NSCLC (Advanced Non-small Cell Lung Cancer)1
  • Solid Tumours1
  • Mesothelioma1
  • Pancreatic Cancer1

Los Angeles, California1 trial

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

Valkyrie Clinical Trials

Phase 1/2

Irving, Texas1 trial

A 2-part Phase 1/2 Open-label Trial on ODM-212

NEXT Oncology

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.